Bibliography
- Lallemant M , JourdainG, Le Coeur S et al.: Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N. Engl. J. Med.351(3) , 217–228 (2004).
- Warszawski J , TubianaR, Le Chenadec J et al.: Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS22(2) , 289–299 (2008).
- Shapiro R , HughesM, OgwuA et al.: A randomized trial comparing highly active antiretroviral therapy regimens for virologic efficacy and the prevention of mother-to-child HIV transmission among breastfeeding women in Botswana (The Mma Bana Study). Presented at: 5th IAS Conference on HIV Pathogenesis and Treatment. Cape Town, South Africa, July 19–22 (2009) (Abstract no. WELBB101).
- Bedri A , GudettaB, IsehakA et al.: Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.Lancet372(9635) , 300–313 (2008).
- Jourdain G , Ngo-Giang-HuongN, Le Coeur S et al.: Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N. Engl. J. Med.351(3) , 229–240 (2004).
- Cressey TR , JourdainG, LallemantMJ et al.: Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.J. Acquir. Immune Defic. Syndr.38(3) , 283–288 (2005).
- Chantarangsu S , CresseyTR, MahasirimongkolS et al.: Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.J. Antimicrob. Chemother.64(6) , 1265–1273 (2009).
- Blanche S , TardieuM, RustinP et al.: Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues.Lancet354(9184) , 1084–1089 (1999).
- Pacheco SE , McIntoshK, LuM et al.: Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: an analysis of the women and infants transmission study.J. Infect. Dis.194(8) , 1089–1097 (2006).
- Mallal S , PhillipsE, CarosiG et al.: HLA-B*5701 screening for hypersensitivity to abacavir.N. Engl. J. Med.358(6) , 568–579 (2008).
- Martin AM , NolanD, JamesI et al.: Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts.AIDS19(1) , 97–99 (2005).
- Chantarangsu S , MushirodaT, MahasirimongkolS et al.: HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients.Pharmacogenet. Genomics19(2) , 139–146 (2009).
- Rodriguez-Novoa S , Martin-CarboneroL, BarreiroP et al.: Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.AIDS21(1) , 41–46 (2007).
- Telenti A : Time (again) for a randomized trial of pharmacogenetics of antiretroviral therapy.Pharmacogenomics10(4) , 515–516 (2009).
- Rodriguez-Novoa S , LabargaP, SorianoV et al.: Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.Clin. Infect. Dis.48(11) , E108–E116 (2009).
▪ Website
- ClinicalTrials.gov identifier: NCT00986063, ClinicalTrials.gov www.clinicaltrials.gov/ct2/show/NCT00986063